• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 14, 2013

View Archived Issues

Pharmacyclics, J&J's Ibrutinib Wins FDA 'Breakthrough' Tag

Pharmacyclics Inc., with partner Janssen Pharmaceuticals Inc., a unit of Johnson & Johnson, became the latest in a small handful of companies to gain "breakthrough therapy designation," a new category that could let drug developers win approval of their drug candidates based on single, Phase I trials. Read More

OIG: Who Knows Whether REMS Improve Drug Safety?

Are risk evaluation and mitigation strategies (REMS) actually making any difference when it comes to drug safety? Enquiring minds at the Health and Human Services' Office of Inspector General (OIG) want to know. The trouble is the FDA doesn't have the data to answer the question. Read More

Taking out Exporter is Double Whammy for S. aureus Toxins

Researchers at the National Institute of Allergy and Infectious Diseases have discovered that by targeting a bacterial transporter Staphylococcus aureus uses to export its toxins, they were able to not only reduce S. aureus virulence, but to kill the bacterium outright. Read More

Trial Design Trips Up Tivozanib, AVEO Pharma Stock Swoons

Stock in AVEO Pharmaceuticals Inc. softened following a clinical trial update released in conjunction with the company's full year 2012 earnings. Trial design may have confounded results for tivozanib, which show overall survival (OS) trends favoring the comparator drug Nexavar (sorafenib, Onyx Pharmaceuticals Inc. and Bayer AG), with OS of 28.8 months for tivozanib and 29.3 months for sorafenib (p = 0. 105). Read More

Trius 'Establishes' Key Endpoints for its Tedizolid Phase III Trial

San Diego-based Trius Therapeutics Inc. said the results from its first pivotal Phase III study of tedizolid phosphate (TR-701) vs. linezolid (Zyvox) completed in 2011 (ESTABLISH 1), have been published in the Journal of the American Medical Association (JAMA). Read More

Stock Movers

Read More

Other News To Note

• Algeta ASA, of Oslo, Norway, said that its partner Bayer AG, of Leverkusen, Germany, has received notification that the New Drug Application (NDA) for the investigational compound Radium Ra 223 Dichloride (radium-223) has been accepted for filing and granted priority review by the FDA. Read More

Clinic Roundup

• Dendreon Corp., of Bridgewater, N.J., reported findings from several ongoing or completed studies of Provenge (sipuleucel-T) in advanced prostate cancer ahead of the 2013 American Society of Clinical Oncology Genitourinary Cancers Symposium in Orlando, Fla. Read More

Pharma: Other News To Note

• Breckenridge Pharmaceutical Inc., of Boca Raton, Fla., said the FDA granted approval of Pioglitazone Hydrochloride tablets, which is being manufactured and supplied by Synthon Pharmaceuticals Inc., and will be available in 15-mg, 30-mg, and 45-mg strengths. Read More

Pharma: Clinic Roundup

• Janssen Research & Development LLC, of Titusville, N.J., a unit of Johnson & Johnson, said updated Phase III results showed Zytiga (abiraterone acetate) plus prednisone continued to provide statistically significant improvements in disease progression compared to placebo plus prednisone, and longer overall survival in men with metastatic castration-resistant prostate cancer. Read More

Earnings Roundup

• Acorda Therapeutics Inc., of Ardsley, N.Y., beat analyst estimates with its net revenues hitting $81.5 million for the fourth quarter vs. the $79.8 million consensus. The company reported GAAP net income of $133 million for the quarter ended Dec. 31, 2012, or $3.27 per diluted EPS. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • Pill with British pound sign

    Pharma execs speak out: UK pricing rebates scare investors

    BioWorld
    The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Kymera’s phase I data lead big week for STAT6 space

    BioWorld
    It’s a good week to be working on drugs targeting STAT6. Kymera Therapeutics Inc.’s, KT-621, the first oral STAT6 degrader candidate to enter the clinic,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe